A groundbreaking personalized CAR-T cell therapy developed by researchers at Johns Hopkins has achieved a 94% complete remission rate in patients with previously untreatable blood cancers.
Super Admin· 5 days ago
Accessibility
Customize your reading experience
Text Size
Default
Display
Settings are saved in your browser. Accessibility features follow WCAG 2.1 guidelines.